We present the updated International Union against Sexually Transmitted Infections (IUSTI) guideline for the management of non-gonococcal urethritis in men. This guideline recommends confirmation of urethritis in symptomatic men before starting treatment. It does not recommend testing asymptomatic men for the presence of urethritis. All men with urethritis should be tested for Chlamydia trachomatis and Neisseria gonorrhoeae and ideally Mycoplasma genitalium using a nucleic acid amplification test (NAAT) as this is highly likely to improve clinical outcomes. If a NAAT is positive for gonorrhoea, a culture should be performed before treatment. In view of the increasing evidence that azithromycin 1 g may result in the development of antimicrobial resistance in M. genitalium, azithromycin 1 g is no longer recommended as first line therapy, which should be doxycycline 100 mg bd for seven days. If azithromycin is to be prescribed an extended course of 500 mg stat, then 250 mg daily for four days is to be preferred over 1 g stat. In men with persistent NGU, M. genitalium NAAT testing is recommended if not previously undertaken, as is Trichomonas vaginalis NAAT testing in populations where T. vaginalis is detectable in >2% of symptomatic women.
. Urethritis should be confirmed by urethral smear microscopy in symptomatic patients . Symptoms and negative urethral smear No empirical treatment. Re-attend for early morning smear if nucleic acid amplification tests (NAATs) are negative and symptoms do not settle
Investigations
. All men assessed for sexually transmitted infections (STIs), regardless of symptoms, should be tested for C. trachomatis from a first void urine (FVU) specimen and for N. gonorrhoeae if they have urethritis. If a NAAT is positive for gonorrhoea, a culture should be performed before treatment. . All men who have sex with men (MSM) should be tested for both C. trachomatis and N. gonorrhoeae from any potentially exposed site.
. Testing male patients with urethritis for M. genitalium, preferably with screening for macrolide resistance, is highly likely to improve clinical outcomes.
Management
. Recommended syndromic regimen: doxycycline 100 mg twice daily for seven days.
Azithromycin 1 g stat should not be used routinely because of the increased risk of inducing macrolide antimicrobial resistance with M. genitalium . If M. genitalium-positive: azithromycin 500 mg stat, then 250 mg od for four days. A test of cure three to five weeks after treatment in those who tested positive for M. genitalium should be performed.
Introduction
Urethritis, or inflammation of the urethra, is a multifactorial condition, which is sexually acquired in the majority of cases. It is characterised by discharge, dysuria and/or urethral discomfort but may be asymptomatic. The diagnosis of urethritis is confirmed by demonstrating an excess of polymorphonuclear leukocytes (PMNLs) in the anterior urethra. This is usually assessed using a urethral smear but a FVU specimen can also be used. Urethritis is described as either gonococcal, when Neisseria gonorrhoeae is detected, or non-gonococcal (NGU) when it is not. The term non-specific urethritis (NSU) applies to non-gonococcal non-chlamydial urethritis and to prevent confusion should be avoided.
There are a number of uncertainties with NGU. There is significant inter-observer and intra-observer error in performing and reading urethral slides and counting polymorphonuclear leucocytes (PMNLs), especially in samples with low-grade inflammation. 1, 2 In many men with urethritis, a known pathogen is not detected. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] 
Aetiology
The prevalence of the common organisms associated with NGU in more recent studies is listed in Table 1 . The commonest organisms implicated are C. trachomatis and M. genitalium, with the latter perhaps causing more symptoms. 4, 5 C. trachomatis and M. genitalium are more likely to be detected in:
. Younger patients with NGU, although this association is not as strong for M. genitalium. 3,5,6 . Those with a urethral discharge and/or dysuria. 3, 6, 7, 35 . C. trachomatis and M. genitalium may be less common in MSM than heterosexual men with NGU. 36 . M. genitalium has been associated with balano-posthitis and C. trachomatis with a circinate balanitis. 25, 37 . The two organisms only infrequently coexist in the same individual with NGU, 38 but dual infections have been identified in up to 10% of men in some studies. 3, 14 . Men with a urethral discharge have a higher bacterial load than those without urethritis. 39, 40 In 30-80% of the cases with NGU, neither C. trachomatis nor M. genitalium is detected. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . The isolation of Trichomonas vaginalis is dependent on the prevalence of the organism in the community (22) (23) (24) (25) (26) (27) (28) . . There is good evidence that U. urealyticum causes urethritis in some men but not all men. 41 Detection even using a NAAT cannot distinguish between asymptomatic carriage and possible causality. 41 The immune response may influence the development of NGU. 15 Also, higher organism load (>1000 copies/ml of FVU) is a stronger predictor of NGU. 42, 43 Earlier studies did not differentiate between the two species Ureaplasma urealyticum (biovar 2) and U. parvum (biovar 1), which continues to be the case if culture alone is used. 41 U. parvum is detected more often in controls than cases, which probably explains why earlier studies failed to demonstrate a consistent association of ureaplasmas with NGU. 41 . There is increasing evidence that bacterial vaginosis (BV)-associated bacteria may cause NGU. [44] [45] [46] . If urinary tract infection is found, young men should be investigated for urinary tract abnormalities. 47 . Adenoviruses or herpes simplex viruses types 1 and 2 may account for 2-4% of symptomatic patients and this may be associated with conjunctivitis. 8, 33, 48 . N. meningitidis, Haemophilus sp., Candida sp., urethral stricture and foreign bodies probably account for a small proportion of NGU, whilst the role of Epstein-Barr virus is questionable. 49, 50 . What causes organism-negative NGU or idiopathic urethritis is unclear. Some of these cases are almost certainly non-infective, but we do not currently have the tools to be able to differentiate probably non-infective from likely infective cases. 51 Asymptomatic urethritis, without an observable discharge, probably has a different aetiology from symptomatic urethritis, with C. trachomatis and M. genitalium being detected less frequently. 4, 5, 7, 52 This guideline does not recommend testing asymptomatic men with urethral microscopy for non-gonococcal urethritis (III, B).
Clinical features
Symptoms.
. Urethral discharge . Dysuria . Penile tip irritation . Urethral discomfort and/or itch . Nil
Signs.
. Urethral discharge . Penile tip erythema . Normal examination Complications.
. Epididymo-orchitis . Sexually acquired reactive arthritis -acute or chronic
Diagnosis
Symptomatic patients and those with a visible discharge should be assessed for the presence of urethritis (IV, C). Urethritis should be confirmed by demonstrating PMNLs from the anterior urethra using a Gramstained or methylene blue-stained urethral smear, which should contain !5 PMNL per high power (hpf) (Â1000) microscopic field (averaged over five fields with greatest concentration of PMNLs). 4, 53, 54 . The quality of the smear is heavily dependent on how the smear is taken and there is both inter-and intra-observer variation when interpreting the result. 1, 2 Either a 5-mm plastic loop or cotton tipped swab can be used, which should be introduced about 1 cm into the urethra 55 (1b) . Other methods are also used, including a sterile blunt curette or spatula 56 (C).
. Based on reported sensitivities of microscopy for detection of chlamydia, blunt curette is more sensitive than a loop, which is better than a swab 4,56-58 (III). . If a urethral discharge is present, the smear can be sampled without placing the device inside the meatus 55 (IV, C). . A viral aetiology is likely if the leukocytes are predominantly mononuclear. 48 An FVU specimen can be examined for threads and, if present, these can be stained and interpreted as for a spun deposit (!10 PMNL/hpf indicates urethritis) 11, 59 (III, B).
Management of symptomatic patients with a negative urethral smear
. If the urethral smear is normal, the patient can be reassured and advised to re-attend for an early morning smear if his symptoms do not settle. He should be advised to hold his urine overnight and to attend not having voided urine. It is good practice to advise the patient to take their last drink at about 8 pm and to void about 3 h later to help avoid waking with a full bladder (IV, C). A leukocyte esterase dipstick on the remains of the FVU specimen may be used to detect urethritis in symptomatic men with a negative urethral smear (54) (IV, C). . Empirical treatment without verifying the presence of urethritis is not recommended, as there is a risk it may perpetuate their symptoms (IV). This treatment should only be given in exceptional circumstances and their partner(s) should also be treated.
The sensitivity of the smear test for diagnosing urethritis, but probably not the FVU in detecting chlamydia, 60, 61 is affected by the period since last passing urine. The optimum time to ensure a definite diagnosis in a symptomatic man is not known; 2-4 h is conventional (IV,C).
Managing patients in settings in which microscopy is not available
Symptomatic patients should be strongly encouraged to attend a centre that has microscopy available because the sensitivity and specificity of other methods for diagnosing urethritis is imperfect compared with a urethral smear. When microscopy is not available, the following can be used to make a diagnosis of urethritis (IV, C):
. The presence of a mucopurulent or purulent urethral discharge on examination . !1þ on a leukocyte esterase dipstick on an FVU specimen (see above) . The presence of threads in a FVU specimen. 62, 63 Threads may be physiological, e.g. semen
Investigations
. Men assessed for STIs should be tested for C. trachomatis from FVU, regardless of symptoms. . Men should be tested for N. gonorrhoeae if they have urethritis. . If N. gonorrhoeae-or C. trachomatis-positive, management should be as specified in the European guidelines. . Testing male patients with urethritis for M. genitalium, preferably with screening for macrolide resistance, is highly likely to improve clinical outcomes. 64 Testing for M. genitalium is therefore recommended. . In men with symptoms strongly suggestive of a urinary tract infection -for example, severe dysuria, haematuria (microscopic or macroscopic), nocturia, urinary frequency or urgency, or is at low risk for an STI, a urinary dipstick analysis on a mid-stream urine specimen should be considered and the sample sent for culture and sensitivities. 47 Although a urinary dipstick is only 68-88% sensitive, it is inexpensive and a useful screening test. 47 If a urinary tract infection is confirmed, consider further urological assessment (IV, C).
General advice
The following should be discussed and clear written information provided:
. An explanation of the causes of NGU, including non-infective causes, and possible short-and longterm implications for the health of the patient and his partner. 
Treatment
Men with severe symptoms should be treated as soon as the diagnosis is made and without waiting for the chlamydia, gonorrhoea and M. genitalium test results. In men with mild symptoms and microscopically proven low-grade urethritis (5-15 PMNLs/hpf), another option is to review the patient after 3-7 days, preferably for an early morning smear, with the results of the NAAT(s) (including M. genitalium) and gonorrhoea culture as sometimes urethritis can resolve without treatment. 65 If laboratory tests are positive, or he has persistent microscopic urethritis, microorganismguided antimicrobial treatment can be administered at the second visit. Ideally, treatment should be effective (microbiological cure >95%), easy to take (twice daily or less), with a low side effect profile, and cause minimal interference with daily lifestyle. However, assessing treatment efficacy is difficult as persistence of inflammation may not indicate persistent infection. 11, 66, 67 Detectable inflammation may persist for an unknown length of time, even when the putative organism has been eliminated. 68 Two recent large randomised controlled trials from the United States observed that both doxycycline and azithromycin are <85% effective with regard to clinical cure. 13, 16 Recommended regimens (grade of recommendation A) Doxycycline 100 mg twice daily (bd) or 200 mg once daily (od) orally for seven days (Ib).
Second line regimens (III, C)
Azithromycin 500 mg single dose (stat), then 250 mg od for four days or azithromycin 1 g stat (azithromycin 1 g stat should not be used routinely because of the increased risk of inducing macrolide antimicrobial resistance with M. genitalium 64, 69 ) Lymecycline 300 mg bd for 10 days Tetracycline hydrochloride 500 mg bd for 10 days If patient is M. genitalium-positive, azithromycin 500 mg stat, then 250 mg od for four days (see above) (III, C)
. Doxycycline 100 mg bd for seven days is >95% effective in men who are chlamydia-positive, 13, 16, [70] [71] [72] [73] and as effective (70-80%) as azithromycin 1 g in men who are U. urealyticum-positive. [74] [75] [76] . Azithromycin 1 g is associated with development of macrolide resistance in M. genitalium 13, 16, 69, [77] [78] [79] , is likely to increase macrolide resistant strains in the population, 64, 69, 80, 81 and has a reduced efficacy in chlamydia-positive men with urethritis. 71, 82, 83 The efficacy of azithromycin may be lower than 80% depending on background macrolide resistance in the population, 64, 78, 80, 84 and M. genitalium-positive men who fail therapy with 1 g are at high risk of developing a 23sRNA gene mutation conferring macrolide resistance. 69, [85] [86] [87] [88] [89] If this were to occur, an extended five-day azithromycin regimen would not be effective at eradicating the infection. 64, 80, 84, 90, 91 . Azithromycin for five days (500 mg stat then 250 mg od for four days) is about 95% effective in eradicating macrolide-susceptible M. genitalium and may be more effective at eradicating chlamydia in men with urethritis. 64, 83, 85, 92, 93 It appears to induce macrolide antimicrobial resistance at a lower rate than the 1 g regimen, although there is limited literature evaluating this. 69, 85, 92 Although macrolide antimicrobial resistance in M. genitalium appears to be worldwide and possibly increasing, it is probably <40% in the majority of countries. 26, 64, 80, 81, 87, 91, 94 . Although never evaluated, using 1 g instead of 500 mg on day 1 maintains the benefits of single dose therapy, and is likely to improve microbiological cure rates and reduce the risk of macrolide resistance developing in M. genitalium (IV). . Lymecycline 300 mg bd for 10 days or tetracycline hydrochloride 500 mg bd for 10 days are probably >95% effective in men who are chlamydia-positive. 95 Unlike doxycycline, these antibiotics do not induce photosensitivity.
Sexual contacts/partners
All sexual partners at risk should be assessed and offered epidemiological treatment, maintaining patient confidentiality. The duration of 'look back' is arbitrary; four weeks is suggested for symptomatic men. Partner(s) notification and management should be carried out with sensitivity, considering socio-cultural issues and avoiding stigma. Current partner(s) should be tested and treated and the patient advised not to be sexually active until all have completed treatment.
If C. trachomatis or N. gonorrhoeae are detected, it is important to ensure that all sexual partner(s) potentially at risk have been notified and managed as detailed in the European chlamydia and gonorrhoea guidelines (available at http://www.iusti.org/regions/europe/euroguidelines.htm).
. Details of all contacts should be obtained at the first visit. Consent should also be obtained, so that if C. trachomatis, N. gonorrhoeae or M. genitalium are detected subsequently and the index patient does not re-attend, he can be contacted and/or provider referral can be initiated for sexual contacts (IV, C).
In a study conducted before NAATs for C. trachomatis and M. genitalium were available, there was no evidence of treatment benefit to partners of men with chlamydia-negative NGU. 96 There are, however, a number of issues, which may influence decision making.
. M. genitalium accounts for approximately 15-30% of cases and there is a high concordance of infection in sexual partners. 97 M. genitalium probably causes disease in women and is a co-factor in HIV transmission. 35, 64, 98 . There are reports of patients with persistent or recurrent ureaplasma-positive urethritis being cured only after their sexual partner received appropriate treatment. 99 
Follow-up for patients with NGU
Patients with persistence of any symptoms, however slight, at three weeks should be asked to return to the clinic and if persistent urethritis is confirmed, retreated with the appropriate regimen (see below) and the possibility of re-infection explored (IV, C). A test of cure three to four weeks after treatment in those who tested positive for M genitalium should be performed. 100 If chlamydia is confirmed (see European guideline), a test of cure is not recommended to be routinely performed in uncomplicated urethritis.
Persistent and recurrent NGU
Persistent NGU, when symptoms do not resolve following treatment, can result from both treatment failure and re-infection. It occurs in 15-25% of patients following initial treatment of acute NGU. Recurrent NGU is empirically defined as the recurrence of symptomatic urethritis occurring 30-90 days following treatment of acute NGU 11 and occurs in 10-20% of patients. 11, 101 The aetiology of persistent NGU is probably multifactorial, with an infectious agent being identified in <50% of cases. 6, 11, 90, 101 M. genitalium has been identified in 20-40% 6, 11, 90, 102 and C. trachomatis in 10-20% of men treated with azithromycin 1 g. 16 U. urealyticum may also play a role in some men, but urethritis appears to resolve despite persistent infection. 11, 74, 76, 103 Trichomonas vaginalis can be identified in up to 10% of populations where it is endemic. 6 Herpes simplex virus should also be considered as this can cause dysuria without signs outside the urethra.
Any treatment of persistent NGU should cover M. genitalium, T. vaginalis and probably BV-associated bacteria. 43, 46, 104 The only randomised controlled trial for persistent NGU was undertaken before M. genitalium had been identified as an important pathogen (but before macrolide resistance was common) and used erythromycin, an older generation macrolide. 105 Although a three-week course was better than placebo, it is not clear how relevant this regimen is today, given that better macrolides are available with fewer side effects. 106 It is likely that re-treatment of the sexual partner and index case will be beneficial if persistent/recurrent NGU in the index case resolves following extended therapy, but subsequently recurs. This remains an area where further research is needed (IV, C).
Diagnosis of persistent/recurrent NGU (IV, C)
. 
Azithromycin prescribed as first line therapy
Moxifloxacin 400 mg orally once daily for 7-14 days (III, B) plus metronidazole 400 mg twice daily for five days (IV, C).
NB: moxifloxacin should be used with caution and reserved for treatment failures, which are thought secondary to macrolide-resistant M. genitalium, because of rare but serious adverse reactions. Australia successfully uses a 10-day course and Nordic countries a seven-day course, whilst no treatment failures have been identified using a 14-day regimen in the United Kingdom. 64, 85, 108, 109 However, a recent study suggests that a 14-day course is more effective than a seven-day course in eradicating M. genitalium in women with cervicitis. 110 In patients having contracted M. genitalium infection in South-East Asia, dual resistance to both macrolides and fluoroquinolones are currently around 10%. Such infections are difficult to treat and only pristinamycin (registered in France) has proven effective on a case basis. 91 
Continuing symptoms
There is only limited evidence on how best to manage patients who either remain symptomatic following a second course of treatment, or who have frequent recurrences after treatment. Testing for M. genitalium is essential to guide management.
. Moxifloxacin 400 mg orally once daily for 7-14 days (IIIb, B). . Urological investigation is usually normal unless the patient has urinary flow problems 111, 112 and is not recommended (IV, C). . The chronic pelvic pain syndrome should be considered in the differential diagnosis. 105, 113, 114 Proposed review date 
